Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$11.85 USD
-0.89 (-6.99%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $11.86 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Olema Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 262 | 204 | 287 | 339 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 4 | 3 | 4 | 0 |
Total Current Assets | 267 | 209 | 291 | 342 | 0 |
Net Property & Equipment | 0 | 1 | 1 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 3 | 1 | 1 | 0 |
Total Assets | 277 | 216 | 296 | 343 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 0 | 0 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 18 | 15 | 8 | 4 | 0 |
Total Current Liabilities | 22 | 17 | 9 | 5 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 23 | 18 | 11 | 5 | 1 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 9 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 559 | 408 | 389 | 371 | 0 |
Retained Earnings | -306 | -209 | -104 | -33 | -11 |
Other Equity | 0 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 254 | 198 | 285 | 338 | -1 |
Total Liabilities & Shareholder's Equity | 277 | 216 | 296 | 343 | 0 |
Total Common Equity | 254 | 198 | 285 | 338 | -11 |
Shares Outstanding | 55.10 | 40.29 | 40.20 | 38.50 | NA |
Book Value Per Share | 4.61 | 4.90 | 7.08 | 8.78 | 0.00 |
Fiscal Year End for Olema Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 239 | 249 | 262 | 277 | 167 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 5 | 5 | 4 |
Total Current Assets | 242 | 252 | 267 | 282 | 172 |
Net Property & Equipment | NA | 0 | 0 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 11 | 10 | 8 | 7 | 3 |
Total Assets | 255 | 264 | 277 | 293 | 178 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 8 | 3 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | 21 | 18 | 18 | 13 | 12 |
Total Current Liabilities | 27 | 26 | 22 | 16 | 15 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 27 | 27 | 23 | 18 | 16 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 594 | 573 | 559 | 554 | 419 |
Retained Earnings | -367 | -337 | -306 | -279 | -257 |
Other Equity | 0 | 0 | 0 | 0 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 227 | 236 | 254 | 275 | 162 |
Total Liabilities & Shareholder's Equity | 255 | 264 | 277 | 293 | 178 |
Total Common Equity | 100,226 | 236 | 254 | 275 | 162 |
Shares Outstanding | 55.93 | 55.93 | 55.10 | 54.60 | 40.70 |
Book Value Per Share | 1,791.99 | 4.23 | 4.61 | 5.04 | 3.97 |